CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation

详细信息    查看全文

• 作者：Max J. Gordon^a ; Paul Tardi^b ; Marc M. Loriaux^c ; ^g ; Stephen E. Spurgeon^d ; ^g ; Elie Traer^d ; ^g ; Tibor Kovacsovics^e ; Lawrence D. Mayer^b ; Jeffrey W. Tyner^f ; ^g ; ^{tynerj@ohsu.edu}
• 关键词：CPX-351 ; Cytarabine ; Daunorubicin ; Leukemia ; Cytotoxicity
• 刊名：Leukemia Research
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：53
• 期：Complete
• 页码：39-49
• 全文大小：1905 K
• 卷排序：53

文摘

CPX-351 is a liposome formulation of cytarabine and daunorubicin in 5:1 molar ratio. CPX-351 has ex vivo activity against a broad range of hematologic malignancies. Consistent with clinical data, CPX-351 activity is retained in high-risk AML blasts. Ex vivo analysis of AML blasts with FLT3-ITD shows increased sensitivity to CPX-351. Ex vivo analysis identifies AML subgroups warranting further clinical investigation.